Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Four H1N1 Vaccines: HHS Touts Fast Response and Improved Infrastructure

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Secretary Sebelius says H1N1 vaccine program has developed at "unprecedented speed"; government support for vaccine industry during past six years makes fast response possible.

You may also be interested in...



Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With Australia's CSL

Merck took its time coming back into the flu vaccine field, but the expansion of world suppliers of vaccines brought a very well-suited partner to its doorstep

Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL

Deal with long-time Australian partner could add up to $100 million to Merck's business in the 2010/2011 flu season, analyst says.

Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL

Deal with long-time Australian partner could add up to $100 million to Merck's business in the 2010/2011 flu season, analyst says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel